NCT05846789 - SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer

Interventions

DRUG

SOC Chemotherapy

SOC Chemotherapy will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

DRUG

Tocilizumab

Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks

Trial Locations (5)

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

RECRUITING

Emory University, Atlanta

RECRUITING

IU Health Joe and Shelly Schwarz Cancer Center, Carmel

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

RECRUITING

Sidney and Lois Eskenazi Hospital, Indianapolis